Study of Radiolabeled ALXN2050 in Healthy Adult Males
Study Identifier:
ALXN2050-HV-106
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: [14C]-ALXN2050
Date
Apr 2021 - Aug 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Male
Age: 19 - 55 Years
Requirements Information
Sex
Male
Age
19 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: [14C]-ALXN2050
Date
Apr 2021 - Aug 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Male
Age: 19 - 55 Years years
Requirements Information
Protocol Summary
This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 (\[14C\])-ALXN2050 in healthy adult males.
Trial Locations
Location
Status
Location
Clinical Trial Site
Lincoln, Nebraska, United States, 68502
Status
N/A